Výsledky vyhľadávania - "Algorithm implementation"
-
1
Autori:
Zdroj: INOVTEK Polbeng - Seri Informatika. 10:1271-1280
-
2
Autori: a ďalší
Zdroj: sinkron. 9:1084-1093
-
3
Autori:
Zdroj: WSEAS TRANSACTIONS ON COMPUTERS. 24:86-91
-
4
Autori: a ďalší
Zdroj: Biocybernetics and Biomedical Engineering. 45:469-475
-
5
Autori: a ďalší
Zdroj: 2025 International Conference on Emerging Technologies in Computing and Communication (ETCC). :1-6
-
6
Autori:
Zdroj: Journal Innovations Computer Science. 4:18-34
-
7
Autori:
Zdroj: Materials of the All-Russian Scientific and Practical Conference «CHALLENGING ISSUES IN SYSTEMS MODELING AND PROCESSES». :245-251
-
8
Autori:
Prispievatelia:
Zdroj: urn:tid:203734114
Predmety: Apriori algorithm, Association rules, Group recommendation systems, Multi-agent systems, Multi-agent microservices, Algoritmo Apriori, Regras de associação, Microserviços multiagente, Sistemas de recomendação para grupos, Sistemas multiagente
Popis súboru: application/pdf
Dostupnosť: http://hdl.handle.net/10400.22/26842
-
9
Prispievatelia: Xiaoying Li, Chief of Endocrinology Department
Zdroj: Effects and Safety of GUideline Algorithm Based Intervention on CaRdiovascular and Renal Outcomes in Elderly Diabetic Patients With High Cardiovascular Risk in the Community- A Cluster Randomized Controlled Trial (GUARD-Community Study)
Gu TW, Zhu DL. [Interpretation of treatment part of national guideline for the prevention and control of diabetes in primary care (2018)]. Zhonghua Nei Ke Za Zhi. 2019 Jul 1;58(7):538-540. doi: 10.3760/cma.j.issn.0578-1426.2019.07.011. Chinese.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum In: Lancet 1999 Aug 14;354(9178):602.
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005 Jan;28(1):164-76. doi: 10.2337/diacare.28.1.164.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486. No abstract available.
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009.
Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 Aug;44(8):1805-1815. doi: 10.2337/dc21-0076. Epub 2021 Jul 7.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. -
10
Autori:
Zdroj: Topics on the Dynamics of Civil Structures, Volume 1 ISBN: 9788743802297
Prístupová URL adresa: https://rd.springer.com/chapter/10.1007/978-1-4614-2413-0_23
https://link.springer.com/content/pdf/10.1007/978-1-4614-2413-0_23.pdf
http://pakzad.atlss.lehigh.edu/wp-content/uploads/2013/01/Iterative-Modal-Identification-Implementation -and-Evaluation.pdf
https://link.springer.com/chapter/10.1007/978-1-4614-2413-0_23 -
11
Autori: Derong Li
Zdroj: 2025 International Conference on Electrical Drives, Power Electronics & Engineering (EDPEE). :522-526
-
12
Autori: Defang Wang
Zdroj: 2025 International Conference on Electrical Drives, Power Electronics & Engineering (EDPEE). :245-250
-
13
Autori: Puneet Gupta
Zdroj: INTERNATIONAL JOURNAL OF INFORMATION TECHNOLOGY AND MANAGEMENT INFORMATION SYSTEMS. 16:513-524
-
14
Autori: a ďalší
Zdroj: 2025 International Conference on Visual Analytics and Data Visualization (ICVADV). :1073-1078
-
15
Autori: a ďalší
Prispievatelia: a ďalší
Zdroj: Energetic Materials Frontiers, Vol 6, Iss 1, Pp 3-13 (2025)
Predmety: Active learning, [STAT.ML]Statistics [stat]/Machine Learning [stat.ML], Materials design, Chemical technology, Thermite, Intelligent sampling, TP1-1185, [SPI.MAT] Engineering Sciences [physics]/Materials, Gaussian process, [STAT.ML] Statistics [stat]/Machine Learning [stat.ML], Performance optimization, [SPI.MAT]Engineering Sciences [physics]/Materials
Popis súboru: application/pdf
-
16
Autori: Lohith Ramesh
Zdroj: International Journal of Advanced Research. 13:880-891
-
17
Autori:
Zdroj: Journal of Computer Science. 21:290-303
-
18
Autori:
Zdroj: 2025 Asia-Europe Conference on Cybersecurity, Internet of Things and Soft Computing (CITSC). :675-679
-
19
Autori: a ďalší
Zdroj: 14th International Conference on Logistics and Systems Engineering (ICLSE 2024). :871-881
-
20
Autori: a ďalší
Zdroj: 2024 International Conference on Augmented Reality, Intelligent Systems, and Industrial Automation (ARIIA). :1-6
Nájsť tento článok vo Web of Science
Full Text Finder